Colchicine

• Gout flare treatment and prevention
• Familial Mediterranean fever
• Pericarditis
• Cardiovascular disease secondary prevention (emerging)

Colchicine is an anti-inflammatory medication with a unique mechanism of action that has been used for centuries to treat gout. Beyond gout, modern clinical trials have established its role in cardiovascular disease prevention and treatment of other inflammatory conditions including familial Mediterranean fever and pericarditis.

Mechanism of Action

Colchicine works primarily by inhibiting microtubule polymerization through binding to tubulin. This disrupts multiple cellular functions including neutrophil migration, chemotaxis, and phagocytosis. By preventing microtubule formation, colchicine inhibits the assembly of the inflammasome, reducing the production of interleukin-1β (IL-1β), a key cytokine in the inflammatory response to urate crystals in gout.

The anti-inflammatory effects extend beyond the inflammasome. Colchicine reduces neutrophil adhesion to endothelium, decreases oxidative stress, and may have direct effects on atherosclerotic plaque stability, which explains its cardiovascular benefits beyond its effects on gout.

Available Formulations

Colchicine is available as oral tablets in 0.6 mg strength (Colcrys) and as oral capsules (Mitigare). An oral solution is available for patients who have difficulty swallowing tablets. The 0.6 mg dose replaced the older 0.5 mg formulation following FDA standardization. Generic formulations are available.

FDA-Approved Indications

Colchicine is FDA-approved for prophylaxis and treatment of gout flares in adults, treatment of familial Mediterranean fever (FMF) in adults and children 4 years and older, and treatment of acute and recurrent pericarditis in adults and children. The COLCOT trial has also established benefits for secondary cardiovascular prevention, though this is not yet an FDA-approved indication.

Dosing Guidelines

For acute gout flare: 1.2 mg at first sign of flare, followed by 0.6 mg one hour later (total 1.8 mg). For gout prophylaxis: 0.6 mg once or twice daily. For FMF: 1.2-2.4 mg daily in divided doses. For pericarditis: Loading dose followed by 0.5-1 mg daily depending on body weight and tolerability. Lower doses are required with renal or hepatic impairment and with certain drug interactions.

Cardiovascular Benefits

The COLCOT trial demonstrated that low-dose colchicine (0.5 mg daily) significantly reduced cardiovascular events in patients with recent myocardial infarction. The LODOCO2 trial showed similar benefits in patients with chronic coronary disease. These findings support the inflammatory hypothesis of atherosclerosis and have expanded the potential uses of colchicine.

Important Safety Considerations

Colchicine has a narrow therapeutic index, and toxicity can be fatal. Symptoms of toxicity include nausea, vomiting, diarrhea, abdominal pain, and may progress to multi-organ failure. The maximum recommended dose for gout flares should not be exceeded. Use is contraindicated in patients with both renal and hepatic impairment. Blood dyscrasias including aplastic anemia, agranulocytosis, and thrombocytopenia have been reported. Neuromyopathy can occur with long-term use.

Drug Interactions

Strong CYP3A4 inhibitors (clarithromycin, ketoconazole, HIV protease inhibitors) and P-glycoprotein inhibitors (cyclosporine) significantly increase colchicine levels and can lead to toxicity; dose reduction is mandatory and repeat dosing must be delayed. Statins and other myotoxic drugs may increase the risk of myopathy. Grapefruit juice should be avoided. Concurrent use with digoxin may increase digoxin levels.

Two Very Different Ways Colchicine Is Used

Colchicine is prescribed in patterns that have little to do with one another, and patients are often confused about which one they are on. The first is rescue treatment for a gout flare, where timing is everything: it works best when taken at the first twinge and does progressively less the longer the flare has been running, which is why patients with recurring flares are given a supply to keep at home rather than being asked to book an appointment when the toe is already swollen. The second is prophylaxis, a small standing dose taken while urate-lowering therapy is being started, because the first months of allopurinol provoke flares and the prophylactic dose is what keeps that phase tolerable.

The third pattern is cardiac. In pericarditis colchicine is added to an anti-inflammatory such as ibuprofen and continued for a course measured in months, because the reason to give it is not the current episode but the recurrence rate afterward; patients who stop early because they feel well lose most of that benefit. Familial Mediterranean fever is a fourth, lifelong use. Whichever pattern applies, the instruction that matters is not to combine the flare regimen and the daily regimen without being told how.

The Checks That Prevent Toxicity

Colchicine has a narrow margin, and almost all serious toxicity comes from one of three situations: kidney or liver impairment that was not accounted for, a drug interaction that raised the level, or a patient repeating doses because the flare did not settle. Kidney and liver function are therefore checked before a standing dose is prescribed and revisited as a patient ages.

The interaction list is short but consequential, and the practical rule is to check before any new antibiotic or antifungal is started. Clarithromycin is the classic example — the combination has caused fatal toxicity — and the same caution applies to certain antifungals, cyclosporine, and HIV protease inhibitors. Grapefruit juice belongs on the list. Statins raise the risk of muscle injury, so new aching or weakness is reported rather than attributed to age. The most useful early warning is the gut: nausea, cramping, and diarrhea appear before anything more serious and mean the dose is too high for that patient, not that the flare needs more drug. The MedlinePlus colchicine monograph and the NIAMS guidance on diagnosing and treating gout cover this for patients, and our article on gout as a misunderstood and rising form of arthritis explains why more people are being started on it.

Special Populations

Dose adjustments are required in renal impairment. In severe renal impairment, lower doses and extended intervals between courses are necessary. Colchicine is contraindicated in patients with both renal and hepatic impairment taking P-gp or strong CYP3A4 inhibitors. Use during pregnancy should weigh benefits against potential risks. Male patients should be aware that colchicine may affect sperm production and function.

Learn more at MedlinePlus